@brooklynstlaurent's GLP-1 investment advice fact-checked

What did @brooklynstlaurent actually say?

Straightforwardly: nothing medical. The transcript is two lines from a song lyric — "Everything's adding up, you've been through hell and back / That's why you're bad as fuck and you know you are." There is no dosing claim, no mechanism of action, no before-and-after assertion. This is a hype video set in a GLP-1 context, not a health tutorial.

The caption adds "your sign to invest in yourself," which functions as a soft call to action. On a platform where GLP-1 content is exploding, that framing does implicit work — it positions a pharmaceutical or telehealth journey as an act of self-love rather than a medical decision. That framing is worth examining even if no factual claim was made aloud.

Does the science back this up?

There is no scientific claim here to test directly. But the emotional pitch — that GLP-1 treatment is a form of self-investment tied to resilience — does touch something real, and the research on patient psychology around these medications is more complicated than a TikTok hype reel suggests.

Studies on GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) do show meaningful weight reduction in clinical trials. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found tirzepatide produced up to 22.5% mean body weight reduction over 72 weeks. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide produced roughly 14.9% weight loss versus 2.4% for placebo. These are real effects. But framing the decision to start a GLP-1 as simply "investing in yourself" skips the part where a clinician evaluates whether you're an appropriate candidate, what your contraindications are, and what discontinuation looks like.

What did they get wrong (or right)?

Credit where it is due: there are no false medical claims here. No one said semaglutide cures anything. No dose was mentioned. No compound was compared to a brand-name drug. From a misinformation standpoint, a video that says nothing medically specific causes less direct harm than one that does.

What the video does do is contribute to a broader content pattern where GLP-1 medications are marketed through identity and aspiration rather than clinical reality. That is not unique to this creator — it is endemic to how these drugs are discussed on social media. Research from Desai et al. (2023, JAMA Internal Medicine) found that the majority of popular social media posts about semaglutide omitted side effects and failed to mention that effects reverse after discontinuation. A video that says "invest in yourself" without any caveats participates in that omission by design.

What should you actually know?

GLP-1 receptor agonists are legitimate, FDA-approved medications with real clinical evidence behind them. They are also not for everyone, and the decision to start one should go through an actual clinician, not a TikTok comment section.

A few things that motivational GLP-1 content routinely leaves out:

• Common side effects include nausea, vomiting, and gastrointestinal distress, which cause a meaningful percentage of patients to reduce dose or discontinue (Wilding et al., 2021, NEJM).
• Weight regain after stopping semaglutide averages about two-thirds of lost weight within one year (Wilding et al., 2022, Diabetes, Obesity and Metabolism).
• Compounded versions of semaglutide and tirzepatide are not FDA-approved and are not equivalent to brand-name Wegovy or Zepbound. The FDA has raised concerns about compounded semaglutide quality and dosing accuracy.
• GLP-1 medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

The emotional framing of "you've been through hell and back" is not inherently harmful. Chronic obesity carries real psychological burden and stigma. But self-compassion is not a substitute for informed consent.